Wall Street Zen upgraded shares of Amphastar Pharmaceuticals (NASDAQ:AMPH – Free Report) from a buy rating to a strong-buy rating in a research report released on Monday morning,Wall Street Zen reports.
A number of other brokerages have also issued reports on AMPH. Wells Fargo & Company lifted their target price on Amphastar Pharmaceuticals from $20.00 to $25.00 and gave the stock an “equal weight” rating in a research report on Friday. Barclays raised their price objective on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the company an “equal weight” rating in a research note on Tuesday, August 18th. Piper Sandler dropped their price objective on Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating on the stock in a report on Friday, August 7th. Weiss Ratings raised Amphastar Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, November 4th. Finally, Zacks Research raised Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 21st. Seven research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Amphastar Pharmaceuticals currently has a consensus rating of “Reduce” and an average price target of $23.33.
View Our Latest Report on AMPH
Amphastar Pharmaceuticals Trading Up 3.1%
NASDAQ AMPH opened at $29.38 on Monday. The stock has a market cap of $1.25 billion, a P/E ratio of 11.21, a PEG ratio of 5.46 and a beta of 0.93. The company’s fifty day simple moving average is $25.50 and its 200-day simple moving average is $22.34. The company has a current ratio of 2.40, a quick ratio of 1.71 and a debt-to-equity ratio of 0.79. Amphastar Pharmaceuticals has a 52 week low of $16.65 and a 52 week high of $31.00.
Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.86 by $0.28. Amphastar Pharmaceuticals had a net margin of 10.76% and a return on equity of 14.98%. The business had revenue of $207.61 million during the quarter, compared to analyst estimates of $197.52 million. Equities research analysts predict that Amphastar Pharmaceuticals will post 2.43 EPS for the current fiscal year.
Insider Buying and Selling at Amphastar Pharmaceuticals
In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 10,000 shares of the business’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $23.94, for a total transaction of $239,400.00. Following the completion of the sale, the executive vice president owned 169,203 shares in the company, valued at $4,050,719.82. The trade was a 5.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO William J. Peters sold 16,000 shares of the business’s stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $28.03, for a total transaction of $448,480.00. Following the sale, the chief financial officer owned 168,707 shares of the company’s stock, valued at approximately $4,728,857.21. The trade was a 8.66% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 45,957 shares of company stock worth $1,232,836 over the last 90 days. 29.60% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the business. Eurizon Capital SGR S.p.A. bought a new stake in shares of Amphastar Pharmaceuticals during the 3rd quarter valued at about $33,000. Nisa Investment Advisors LLC lifted its holdings in Amphastar Pharmaceuticals by 183.3% in the third quarter. Nisa Investment Advisors LLC now owns 1,422 shares of the company’s stock worth $37,000 after acquiring an additional 920 shares during the last quarter. Quantbot Technologies LP bought a new position in Amphastar Pharmaceuticals in the second quarter worth about $39,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in Amphastar Pharmaceuticals in the third quarter valued at approximately $56,000. Finally, State of Wyoming acquired a new position in Amphastar Pharmaceuticals in the second quarter valued at approximately $142,000. 65.09% of the stock is currently owned by institutional investors.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc is a biopharmaceutical company that develops, manufactures and markets injectable, inhalation and intranasal products. The company focuses on technically challenging medicines, including complex generics, proprietary products and products based on its drug-delivery technologies.
Its product portfolio includes Primatene MIST, an over-the-counter epinephrine inhaler; Baqsimi, a nasal glucagon product used to treat severe hypoglycemia; and injectable medicines such as glucagon, naloxone, enoxaparin and hyaluronidase.
Featured Articles
- Five stocks we like better than Amphastar Pharmaceuticals
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
